Restricted accessResearch articleFirst published online 2025-04
Absence of Evidence for Sustained Effects of Daily Cannabidiol Administration on Anandamide Plasma Concentration in Individuals with Cocaine Use Disorder: Exploratory Findings from a Randomized Controlled Trial
Cannabidiol (CBD) has been proposed to have a therapeutic potential over a wide range of neuropsychiatric disorders, including substance use disorders. Pre-clinical evidence suggests that CBD can increase anandamide (AEA) plasma concentration, possibly mediating some of its therapeutic properties. Whether CBD exerts such an effect on AEA in individuals with cocaine use disorder (CUD) remains unknown.
Aims:
To explore the sustained effects of daily CBD administration on AEA plasma concentrations compared with placebo in CUD.
Methods:
We used data from a randomized, double-blind, placebo-controlled trial evaluating CBD’s efficacy in CUD. Seventy-eight individuals were randomized to receive a daily oral dose of 800 mg CBD (n = 40) or a placebo (n = 38). Participants stayed in an inpatient detoxification setting for 10 days, after which they were followed in an outpatient setting for 12 weeks. AEA plasma concentration was measured at baseline and at 23-h post CBD ingestion on day 8 and week 4. A generalized estimating equation model was used to assess CBD’s effects on AEA, and sensitivity analyses were computed using Bayesian linear regressions.
Results:
Sixty-four participants were included in the analysis. Similar mean AEA plasma concentrations in both treatment groups (p = 0.357) were observed. At day 8, mean AEA plasma concentrations (± standard deviation) were 0.26 (± 0.07) ng/mL in the CBD group and 0.29 (± 0.08) ng/mL in the placebo group (p = 0.832; Bayes factor [BF] = 0.190). At week 4, they were 0.27 (± 0.09) ng/mL in the CBD group and 0.30 (± 0.09) ng/mL in the placebo group (p = 0.181; BF = 0.194).
Conclusion:
While not excluding any potential acute and short-term effect, daily CBD administration did not exert a sustained impact on AEA plasma concentrations in individuals with CUD compared with placebo.
Registration:
clinicaltrials.gov (NCT02559167).
Get full access to this article
View all access options for this article.
References
1.
United Nations Offices on Drugs Crime. World Drug Report 2020. United Nations Publications.
2.
NestlerEJ. The neurobiology of cocaine addiction. SPP. 2005; 3(1):4–10; doi: 10.1151/spp05314
3.
WangH, TreadwayT, CoveyDP, et al.Cocaine-Induced endocannabinoid mobilization in the ventral tegmental area. Cell Rep. 2015; 12(12):1997–2008; doi: 10.1016/j.celrep.2015.08.041
4.
SchermaM, MasiaP, SattaV, et al.Brain activity of anandamide: A rewarding bliss? Acta Pharmacol Sin. 2019; 40(3):309–323; doi: 10.1038/s41401-018-0075-x
5.
MarzoVD. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov. 2008; 7(5):438–455; doi: 10.1038/nrd2553
6.
RussoEB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2004; 25(1-2):31–39.
7.
ParolaroD, ViganoD, RealiniN, et al.Role of endocannabinoids in regulating drug dependence. Neuropsychiatr Dis Treat. 2007; 3(6):711–721; doi: 10.2147/ndt.s976
8.
OrioL, EdwardsS, GeorgeO, et al.A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. J Neurosci. 2009; 29(15):4846–4857; doi: 10.1523/JNEUROSCI.0563-09.2009
HasinDS, KerridgeBT, SahaTD, et al.Prevalence and Correlates of DSM-5 cannabis use disorder, 2012-2013: Findings from the national epidemiologic survey on alcohol and related conditions–III. Am J Psychiatry. 2016; 173(6):588–599; doi: 10.1176/appi.ajp.2015.15070907
11.
DegenhardtL, FerrariAJ, CalabriaB, et al.The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: Results from the GBD 2010 study. PLoS One. 2013; 8(10):e76635; doi: 10.1371/journal.pone.0076635
12.
BrancatoA, CastelliV, LavancoG, et al.Binge-like alcohol exposure in adolescence: Behavioural, neuroendocrine and molecular evidence of abnormal neuroplasticity… and return. Biomed. 2021; 9(9):1161; doi: 10.3390/biomedicines9091161
13.
BrancatoA, CastelliV, LavancoG, et al.Social stress under binge-like alcohol withdrawal in adolescence: Evidence of cannabidiol effect on maladaptive plasticity in rats. Psychol Med. 2022; 53(12):5538–5550; doi: 10.1017/S0033291722002744
14.
Calpe-LópezC, García-PardoMP, AguilarMA. Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms. Molecules. 2019; 24(14):2583; doi: 10.3390/molecules24142583
15.
RodriguesLA, CarobaMES, TabaFK, et al.Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review. Pharmacol Biochem Behav. 2020; 196:172982; doi: 10.1016/j.pbb.2020.172982
16.
FreemanTP, HindochaC, BaioG, et al.Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020; 7(10):865–874; doi: 10.1016/S2215-0366(20)30290-X
17.
HurdYL, SpriggsS, AlishayevJ, et al.Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019; 176(11):911–922; doi: 10.1176/appi.ajp.2019.18101191
18.
LewekeFM, PiomelliD, PahlischF, et al.Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 2(3):e94–e94; doi: 10.1038/tp.2012.15
19.
KathuriaS, GaetaniS, FegleyD, et al.Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003; 9(1):76–81; doi: 10.1038/nm803
20.
GaetaniS, CuomoV, PiomelliD. Anandamide hydrolysis: A new target for anti-anxiety drugs? Trends Mol Med. 2003; 9(11):474–478; doi: 10.1016/j.molmed.2003.09.005
21.
LuchicchiA, PistisM. Anandamide and 2-arachidonoylglycerol: Pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol. 2012; 46(2):374–392; doi: 10.1007/s12035-012-8299-0
22.
SolinasM, JustinovaZ, GoldbergSR, et al.Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem. 2006; 98(2):408–419; doi: 10.1111/j.1471-4159.2006.03880.x
23.
BisognoT, HanusL, De PetrocellisL, et al.Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001; 134(4):845–852; doi: 10.1038/sj.bjp.0704327
24.
MarzoVD. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018; 17(9):623–639; doi: 10.1038/nrd.2018.115
25.
LuchicchiA, LeccaS, CartaS, et al.Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: Involvement of PPAR-alpha nuclear receptors. Addict Biol. 2010; 15(3):277–288; doi: 10.1111/j.1369-1600.2010.00222.x
26.
SchermaM, JustinováZ, ZanettiniC, et al.The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine‐induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol. 2012; 165(8):2539–2548; doi: 10.1111/j.1476-5381.2011.01467.x
27.
CippitelliA, AstaritaG, DurantiA, et al.Endocannabinoid regulation of acute and protracted nicotine withdrawal: Effect of FAAH inhibition. PLoS One. 2011; 6(11):e28142; doi: 10.1371/journal.pone.0028142
28.
WilkersonJL, GhoshS, MustafaM, et al.The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology. 2017; 114:156–167; doi: 10.1016/j.neuropharm.2016.11.015
29.
RameshD, GamageTF, VanuytselT, et al.Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology. 2013; 38(6):1039–1049; doi: 10.1038/npp.2012.269
30.
ElmesMW, KaczochaM, BergerWT, et al.Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). J Biol Chem. 2015; 290(14):8711–8721; doi: 10.1074/jbc.M114.618447
31.
PetrosinoS, VerdeR, VaiaM, et al.Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J Pharmacol Exp Ther. 2018; 365(3):652–663; doi: 10.1124/jpet.117.244368
32.
De PetrocellisL, LigrestiA, MorielloAS, et al.Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011; 163(7):1479–1494; doi: 10.1111/j.1476-5381.2010.01166.x
33.
SahinovicA, IrwinC, DoohanPT, et al.Effects of cannabidiol on exercise physiology and bioenergetics: A randomised controlled pilot trial. Sports Med Open. 2022; 8(1):27; doi: 10.1186/s40798-022-00417-y
34.
AbuhasiraR, AzarS, NemirovskiA, et al.Herbal cannabis use is not associated with changes in levels of endocannabinoids and metabolic profile alterations among older adults. Life (Basel). 2022; 12(10):1539; doi: 10.3390/life12101539
35.
HuaDY-H, HindochaC, BaioG, et al.Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: Findings from a randomised clinical trial for the treatment of cannabis use disorder. Transl Psychiatry. 2023; 13(1):131; doi: 10.1038/s41398-023-02410-9
36.
ChesterLA, EnglundA, ChesneyE, et al.Effects of cannabidiol and delta-9-tetrahydrocannabinol on plasma endocannabinoid levels in healthy volunteers: A randomized double-blind four-arm crossover study. Cannabis Cannabinoid Res. 2024; 9(1):188–198; doi: 10.1089/can.2022.0174
37.
Mongeau-PérusseV, BrissetteS, BruneauJ, et al.Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo‐controlled trial. Addiction. 2021; 116(9):2431–2442; doi: 10.1111/add.15417
38.
MorissetteF, Mongeau-PérusseV, RizkallahE, et al.Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: A randomized controlled trial. Neuropsychopharmacology. 2021; 46(12):2101–2111; doi: 10.1038/s41386-021-01098-z
39.
FirstM, KargR, SpitzerR, et al.Structured Clinical Interview for DSM-5 (SCID-5 for DMS-5). editor. Arlington: American Psychiatric Association Publishing; 2017.
40.
SheehanDV, LecrubierY, SheehanKH, et al.The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20):22–33.
41.
FoxHC, GarciaM, KempK, et al.Gender differences in cardiovascular and corticoadrenal response to stress and drug cues in cocaine dependent individuals. Psychopharmacology (Berl). 2006; 185(3):348–357; doi: 10.1007/s00213-005-0303-1
42.
FerriCP, DunnJ, GossopM, et al.Factors associated with adverse reactions to cocaine among a sample of long-term, high-dose users in São Paulo, Brazil. Addict Behav. 2004; 29(2):365–374; doi: 10.1016/j.addbeh.2003.08.029
43.
IfflandK, GrotenhermenF. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017; 2(1):139–154; doi: 10.1089/can.2016.0034
44.
LanzC, MattssonJ, StickelF, et al.Determination of the endocannabinoids anandamide and 2-Arachidonoyl glycerol with gas chromatography-mass spectrometry: Analytical and preanalytical challenges and pitfalls. Med Cannabis Cannabinoids. 2018; 1(1):9–18; doi: 10.1159/000489032
45.
MarchioniC, de SouzaID, GreccoCF, et al.A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples. Anal Bioanal Chem. 2017; 409(14):3587–3596; doi: 10.1007/s00216-017-0300-3
46.
ZoernerAA, BatkaiS, SuchyM-T, et al.Simultaneous UPLC–MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: Minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 883-884:161–171; doi: 10.1016/j.jchromb.2011.06.025
47.
El-TalatiniMR, TaylorAH, KonjeJC. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril. 2010; 93(6):1989–1996; doi: 10.1016/j.fertnstert.2008.12.033
48.
DesfossésJ, StipE, BentalebLA, et al.Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the “Mirror Effect” of schizophrenia. Front Psychiatry. 2012; 3:85; doi: 10.3389/fpsyt.2012.00085
49.
GossopM, DarkeS, GriffithsP, et al.The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995; 90(5):607–614; doi: 10.1046/j.1360-0443.1995.9056072.x
50.
BeardE, DienesZ, MuirheadC, et al.Using Bayes factors for testing hypotheses about intervention effectiveness in addictions research: Using Bayes factors for testing hypotheses about intervention effectiveness in addictions research. Addiction. 2016; 111(12):2230–2247; doi: 10.1111/add.13501
51.
WetzelsR, WagenmakersEJ. A default Bayesian hypothesis test for correlations and partial correlations. Psychon Bull Rev. 2012; 19(6):1057–1064; doi: 10.3758/s13423-012-0295-x
PavónFJ, AraosP, PastorA, et al.Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: Impact of psychiatric co-morbidity. Addict Biol. 2013; 18(6):955–969; doi: 10.1111/adb.12107
54.
KrollSL, HulkaLM, KexelA-K, et al.Plasma endocannabinoids in cocaine dependence and their relation to cerebral metabotropic glutamate receptor 5 density. Transl Psychiatry. 2023; 13(1):325; doi: 10.1038/s41398-023-02628-7
55.
ToczekM, MalinowskaB. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 2018; 204:20–45; doi: 10.1016/j.lfs.2018.04.054
56.
Mongeau-PérusseV, RizkallahE, MorissetteF, et al.Cannabidiol effect on anxiety symptoms and stress response in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. J Addict Med. 2022; 16(5):521–526; doi: 10.1097/ADM.0000000000000959
57.
MahoneyJJ, De La GarzaR, JacksonBJ, et al.The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res. 2014; 219(2):367–371; doi: 10.1016/j.psychres.2014.05.026
58.
HillardCJ. Circulating endocannabinoids: From whence do they come and where are they going? Neuropsychopharmacology. 2018; 43(1):155–172; doi: 10.1038/npp.2017.130
59.
IbsenMS, ConnorM, GlassM. Cannabinoid CB1 and CB2 receptor signaling and bias. Cannabis Cannabinoid Res. 2017; 2(1):48–60; doi: 10.1089/can.2016.0037
60.
LiuJ, WangL, Harvey-WhiteJ, et al.A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A. 2006; 103(36):13345–13350; doi: 10.1073/pnas.0601832103
61.
BisognoT, SepeN, MelckD, et al.Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J. 1997; 322 (Pt 2)(Pt 2):671–677; doi: 10.1042/bj3220671
62.
HowlettAC, ReggioPH, ChildersSR, et al.Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol. 2011; 163(7):1329–1343; doi: 10.1111/j.1476-5381.2011.01364.x
63.
BystrowskaB, FrankowskaM, SmagaI, et al.Cocaine-Induced reinstatement of cocaine seeking provokes changes in the endocannabinoid and N-acylethanolamine levels in rat brain structures. Molecules. 2019; 24(6):1125; doi: 10.3390/molecules24061125
64.
PalominoA, PavónF-J, Blanco-CalvoE, et al.Effects of acute versus repeated cocaine exposure on the expression of endocannabinoid signaling-related proteins in the mouse cerebellum. Front Integr Neurosci. 2014; 8:22; doi: 10.3389/fnint.2014.00022
65.
CentonzeD, BattistaN, RossiS, et al.A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology. 2004; 29(8):1488–1497; doi: 10.1038/sj.npp.1300458
66.
ArnoldJC. The role of endocannabinoid transmission in cocaine addiction. Pharmacol Biochem Behav. 2005; 81(2):396–406; doi: 10.1016/j.pbb.2005.02.015
67.
ZamarripaCA, VandreyR, SpindleTR. Factors that impact the pharmacokinetic and pharmacodynamic effects of cannabis: A review of human laboratory studies. Curr Addict Rep. 2022; 9(4):608–621; doi: 10.1007/s40429-022-00429-4
68.
NedelescuH, WagnerGE, De NessGL, et al.Cannabidiol produces distinct u-shaped dose-response effects on cocaine-induced conditioned place preference and associated recruitment of prelimbic neurons in male rats. Biol Psychiatry Glob Open Sci. 2022; 2(1):70–78; doi: 10.1016/j.bpsgos.2021.06.014
69.
QinC, HuJ, WanY, et al.Narrative review on potential role of gut microbiota in certain substance addiction. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 106:110093; doi: 10.1016/j.pnpbp.2020.110093
70.
SempioC, KlawitterJ, De BlooisE, et al.Acute effects of cannabinoid consumption on endocannabinoid levels. Toxicol Anal Et Clinique. 2022; 34(3):S22; doi: 10.1016/j.toxac.2022.06.009
71.
CuiN, WangL, WangW, et al.The correlation of anandamide with gonadotrophin and sex steroid hormones during the menstrual cycle. Iran J Basic Med Sci. 2017; 20(11):1268–1274; doi: 10.22038/IJBMS.2017.9488
72.
CorroonJ, FeliceJF. The Endocannabinoid System and its Modulation by Cannabidiol (CBD). Altern Ther Health Med. 2019; 25(S2):6–14.
73.
Castonguay-ParadisS, LacroixS, RochefortG, et al.Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. Sci Rep. 2020; 10(1):15975; doi: 10.1038/s41598-020-72861-3
74.
SpanagelR. Cannabinoids and the endocannabinoid system in reward processing and addiction: From mechanisms to interventions. Dialogues Clin Neurosci. 2020; 22(3):241–250; doi: 10.31887/DCNS.2020.22.3/rspanagel
75.
BermanP, SulimaniL, GelfandA, et al.Cannabinoidomics—An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome. Talanta. 2020; 219:121336; doi: 10.1016/j.talanta.2020.121336
76.
RussoEB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2018; 9:1969; doi: 10.3389/fpls.2018.01969
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
